<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The study aimed to determine whether <z:chebi fb="0" ids="15864">luteolin</z:chebi> can confer cardioprotective effects against diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in relation to specific and quantitative markers of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We examined diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> by left ventricular hemodynamic analysis </plain></SENT>
<SENT sid="2" pm="."><plain>Myocardial <z:mp ids='MP_0003674'>oxidative stress</z:mp> was assessed by measuring the activity of <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) as well as the level of malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>Hypolipidaemic effects of <z:chebi fb="0" ids="15864">luteolin</z:chebi> were also investigated in STZ-induced diabetic rats </plain></SENT>
<SENT sid="4" pm="."><plain>Myocardial Akt/PKB phosphorylation, <z:chebi fb="4" ids="30413">heme</z:chebi> oxygenase-1 (HO-1) and connective tissue growth factor (CTGF) protein levels were measured by Western blot in <z:hpo ids='HP_0000001'>all</z:hpo> rats at the end of the study </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: This study showed a significant increase in serum triacylglycerol (TG), total cholesterol (TC), lower density <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>), <z:chebi fb="14" ids="32506">MDA</z:chebi> content, <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase (CK), <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH), and myocardial CTGF and a significant decrease in <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>), SOD and Akt phosphorylation level in the diabetic group compared to the control group </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi> treatment induced a significant decrease in serum TG, TC, <z:chebi fb="15" ids="39026">LDL</z:chebi>, <z:chebi fb="14" ids="32506">MDA</z:chebi>, CK, LDH, and myocardial CTGF and a significant increase in <z:chebi fb="17" ids="39025">HDL</z:chebi>, SOD and Akt phosphorylation levels in comparison with the diabetic group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: These results show that <z:chebi fb="0" ids="15864">luteolin</z:chebi> protects against the progression of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>-induced cardiac dysfunction by attenuation of myocardial <z:mp ids='MP_0003674'>oxidative stress</z:mp> probably through its <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties </plain></SENT>
</text></document>